Advertisement

A Translational Approach to Evaluate the Efficacy and Safety of the Novel AMPA Receptor Positive Allosteric Modulator Org 26576 in Adult Attention-Deficit/Hyperactivity Disorder

      Background

      It has been posited that glutamate dysregulation contributes to the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). Modulation of glutamate neurotransmission may provide alternative therapeutic options. The novel 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid receptor positive allosteric modulator Org 26576 was investigated with a translational approach including preclinical and clinical testing.

      Methods

      Neonatal rat 6-hydroxydopamine lesion-induced hyperactivity was used as preclinical model. Seventy-eight ADHD adults entered a multicenter, double-blind, placebo-controlled, two-period crossover trial. After 1 week placebo lead-in, 67 subjects were randomized into one of four treatment sequences: sequence A (n = 15) Org 26576 (100 mg b.i.d.) for 3 weeks, followed by a 2-week placebo crossover and 3 weeks placebo; sequence B (n = 16) 5 weeks placebo followed by 3 weeks Org 26576 (100 mg b.i.d.); sequence C (n = 18) Org 26576 flexible dose (100–300 mg b.i.d.) for 3 weeks, then 5 weeks placebo; sequence D (n = 18) 5 weeks placebo followed by 3 weeks Org 26576 (100–300 mg b.i.d.). The Adult ADHD Investigator Symptom Rating Scale was used to assess changes in ADHD symptomatology.

      Results

      Org 26576 (1, 3, 10 mg/kg intraperitoneal) produced dose-dependent inhibition of locomotor hyperactivity in 6-hydroxydopamine-lesioned rats. Org 26576 (100 mg b.i.d.) was superior to placebo in treating symptoms of adult ADHD subjects. The primary Adult ADHD Investigator Symptom Rating Scale results were supported by some secondary analyses. However, Org 26576 (100–300 mg b.i.d.) did not confirm these results. Most frequently reported adverse events were nausea, dizziness, and headache.

      Conclusions

      These preclinical and clinical findings suggest that Org 25676 may have utility in the treatment of ADHD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adler L.
        • Cohen J.
        Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.
        Psychiatr Clin North Am. 2004; 27: 187-201
        • Kessler R.C.
        • Chiu W.T.
        • Demler O.
        • Merikangas K.R.
        • Walters E.E.
        Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.
        Arch Gen Psychiatry. 2005; 62: 617-627
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. American Psychiatric Press, Washington, DC2000
        • Wilens T.E.
        • Biederman J.
        • Brown S.
        • Tanguay S.
        • Monuteaux M.C.
        • Blake C.
        • Spencer T.J.
        Psychiatric comorbidity and functioning in clinically-referred preschool children and school-age youth with ADHD.
        J Am Acad Child Adolesc Psychiatry. 2002; 41: 262-268
        • Biederman J.
        • Wilens T.
        • Mick E.
        • Faraone S.V.
        • Weber W.
        • Curtis S.
        • et al.
        Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study.
        J Am Acad Child Adolesc Psychiatry. 1997; 36: 21-29
        • Pliszka S.R.
        • McCracken J.T.
        • Maas J.W.
        Catecholamines in attention deficit/hyperactivity disorder: Current perspectives.
        J Am Acad Child Adolesc Psychiatry. 1996; 35: 264-272
        • Biederman J.
        • Faraone S.V.
        • Keenan K.
        • Benjamin J.
        • Krifcher B.
        • Moore C.
        • et al.
        Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples.
        Arch Gen Psychiatry. 1992; 49: 728-738
        • Dopheide J.A.
        • Pliszka S.R.
        Attention-deficit-hyperactivity disorder: An update.
        Pharmacotherapy. 2009; 29: 656-679
        • Kooij J.J.
        • Burger H.
        • Boonstra A.M.
        • Van der Linden P.D.
        • Kalma L.E.
        • Buitelaar J.K.
        Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder.
        Psychol Med. 2004; 34: 973-982
        • Hammerness P.
        • Biederman J.
        • Petty C.
        • Henin A.
        • Moore C.M.
        Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: A controlled pilot study.
        CNS Neurosci Ther. 2012; 18: 34-40
        • Elia J.
        • Gai X.
        • Xie H.M.
        • Perin J.C.
        • Geiger E.
        • Glessner J.T.
        • et al.
        Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes.
        Mol Psychiatry. 2010; 15: 637-646
        • Perlov E.
        • Philipsen A.
        • Hesslinger B.
        • Buechert M.
        • Ahrendts J.
        • Feige B.
        • et al.
        Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder–a magnet resonance spectroscopy study.
        J Psychiatr Res. 2007; 41: 934-941
        • Shaw P.
        • Rabin C.
        New insights into attention-deficit/hyperactivity disorder using structural neuroimaging.
        Curr Psychiatry Rep. 2009; 11: 393-398
        • Dorval K.M.
        • Wigg K.G.
        • Crosbie J.
        • Tannock R.
        • Kennedy J.L.
        • Ickowicz A.
        • et al.
        Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder.
        Genes Brain Behav. 2007; 6: 444-452
        • Carlsson M.L.
        On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions.
        Acta Psychiatr Scand. 2000; 102: 401-413
        • Lehohla M.
        • Kellaway L.
        • Russell V.A.
        NMDA receptor function in the prefrontal cortex of a rat model for attention-deficit hyperactivity disorder.
        Metab Brain Dis. 2004; 19: 35-42
        • Ruocco L.A.
        • Gironi Carnevale U.A.
        • Sadile A.G.
        • Sica A.
        • Arra C.
        • Di Maio A.
        • et al.
        Elevated forebrain excitatory L-glutamate, L-aspartate and D-aspartate in the Naples high-excitability rats.
        Behav Brain Res. 2009; 198: 24-28
        • Jensen V.
        • Rinholm J.E.
        • Johansen T.J.
        • Medin T.
        • Storm-Mathisen J.
        • Sagvolden T.
        • et al.
        N-methyl-D-aspartate receptor subunit dysfunction at hippocampal glutamatergic synapses in an animal model of attention-deficit/hyperactivity disorder.
        Neuroscience. 2009; 158: 353-364
        • Warton F.L.
        • Howells F.M.
        • Russell V.A.
        Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder–lack of effect of methylphenidate.
        Metab Brain Dis. 2009; 24: 599-613
        • Russell V.A.
        Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder–the spontaneously hypertensive rat.
        Neurosci Biobehav Rev. 2003; 27: 671-682
        • Russell V.A.
        • Wiggins T.M.
        Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats.
        Metab Brain Dis. 2000; 15: 297-304
        • Zhang K.
        • Tarazi F.I.
        • Baldessarini R.J.
        Role of dopamine D4 receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats.
        Neuropsychopharmacology. 2001; 25: 624-632
        • Adler L.
        • Cohen J.
        Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.
        Psychiatr Clin North Am. 2004; 27: 187-201
        • Guy W.
        Clinical global impressions.
        in: Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, Rockville, MD1976: 217-222
        • Spencer T.J.
        • Adler L.A.
        • Meihua Q.
        • Saylor K.E.
        • Brown T.E.
        • Holdnack J.A.
        • et al.
        Validation of the adult ADHD investigator symptom rating scale (AISRS).
        J Atten Disord. 2010; 14: 57-68
        • First M.B.
        • Williams J.B.W.
        • Spitzer R.L.
        • Gibbon M.
        Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). Biometrics Research, New York State Psychiatric Institute, New York2007
      1. Beck AT, Steer RA (1001): Manual for the Beck Scale for Suicide Ideation. San Antonio, TX: Psychological Corporation.

        • Adler L.A.
        • Spencer T.
        • Faraone S.V.
        • Reimherr F.W.
        • Kelsey D.
        • Michelson D.
        • Biederman J.
        Training raters to assess adult ADHD: Reliability of ratings.
        J Atten Disord. 2005; 8: 121-126
        • Johns M.W.
        A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale.
        Sleep. 1991; 14: 540-545
        • Buysse D.J.
        • Reynolds C.F.
        • Monk T.H.
        • Berman S.R.
        • Kupfer D.J.
        The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research.
        Psychiatry Res. 1988; 28: 193-213
        • Rush A.J.
        • Trivedi M.H.
        • Ibrahim H.M.
        • Carmody T.J.
        • Arnow B.
        • Klein D.N.
        • et al.
        The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression.
        Biol Psychiatry. 2003; 54: 573-583
        • Adler L.A.
        • Shaw D.M.
        • Spencer T.J.
        • Newcorn J.H.
        • Sitt D.J.
        • Morrill M.
        • et al.
        Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults.
        Compr Psychiatry. 2011; 52: 769-773
        • Michelson D.
        • Adler L.A.
        • Spencer T.
        • Reimherr F.W.
        • West S.A.
        • Allen A.J.
        • et al.
        Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies.
        Biol Psychiatry. 2003; 53: 112-120
        • Faraone S.V.
        • Glatt S.J.
        A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
        J Clin Psychiatry. 2010; 71: 754-763
        • Kostrzewa R.M.
        • Kostrzewa J.P.
        • Kostrzewa R.A.
        • Nowak P.
        • Brus R.
        Pharmacological models of ADHD.
        J Neural Transm. 2008; 115: 287-298
        • Davids E.
        • Zhang K.
        • Tarazi F.I.
        • Baldessarini R.J.
        Animal models of attention-deficit hyperactivity disorder.
        Brain Res Brain Res Rev. 2003; 42: 1-2
        • Erdemli G.
        • Sammons M.
        • Shahid M.
        • Jeggo R.
        • Smith L.H.
        Org 26576, a novel positive allosteric modulator, potentiates AMPA receptor responses in hippocampal neurones.
        Eur Neuropsychopharmacol. 2007; 17: S486
        • Jordan G.R.
        • McCulloch J.
        • Shahid M.
        • Hill D.R.
        • Henry B.
        • Horsburgh K.
        Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography.
        Neuropharmacology. 2005; 49: 254-264
        • Bursi R.
        • Erdemli G.
        • Campbell R.
        • Hutmacher M.M.
        • Kerbusch T.
        • Spanswick D.
        • et al.
        Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.
        Psychopharmacology (Berl). 2011; 218: 713-724
        • Hamlyn E.
        • Brand L.
        • Shahid M.
        • Harvey B.H.
        The ampakine Org 26576 bolsters early spatial reference learning and retrieval in the Morris water maze: A subchronic, dose-ranging study in rats.
        Behav Pharmacol. 2009; 20: 662-667
        • Gainetdinov R.R.
        • Mohn A.R.
        • Bohn L.M.
        • Caron M.G.
        Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.
        Proc Natl Acad Sci U S A. 2001; 98: 11047-11054
      2. Adler LA, Stein MA, Mansbach H (2006): Treatment of adult ADHD with the novel ampakine CX717 (poster). Presented at the 53rd Annual Meeting of the American Academy of Adolescent and Child Psychiatry, San Diego, California, 24-29 October 2006.

        • Kessler R.C.
        • Green J.G.
        • Adler L.A.
        • Barkley R.A.
        • Chatterji S.
        • Faraone S.V.
        • et al.
        Structure and diagnosis of adult attention-deficit/hyperactivity disorder analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale.
        Arch Gen Psychiatry. 2010; 67: 1168-1178
        • Millstein R.B.
        • Wilens T.E.
        • Biederman J.
        • Spencer T.J.
        Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD.
        J Atten Disord. 1997; 2: 159-166
        • Newcorn J.H.
        • Sutton V.K.
        • Zhang S.
        • Wilens T.
        • Kratochvil C.
        • Emslie G.J.
        • et al.
        Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.
        J Am Acad Child Adolesc Psychiatry. 2009; 48: 1165-1172
        • Waxmonsky J.G.
        • Waschbusch D.A.
        • Glatt S.J.
        • Faraone S.V.
        Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
        J Clin Psychiatry. 2011; 72: 1366-1375